Drug Profile
Research programme: oncolytic virus therapeutics - Neotropix
Alternative Names: NTX-100; NTX-250; NTX-400; NTX-420; NTX-500; NTX-800Latest Information Update: 16 Jun 2011
Price :
$50
*
At a glance
- Originator Neotropix
- Class Oncolytic viruses
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jun 2011 Research programme: oncolytic virus therapeutics - Neotropix is available for licensing. http://www.neotropix.com
- 22 Feb 2011 Crucell has been acquired by Johnson & Johnson
- 05 Sep 2007 Preclinical development is ongoing